Pages that link to "Q36674580"
Jump to navigation
Jump to search
The following pages link to Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept (Q36674580):
Displaying 7 items.
- Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model (Q32172336) (← links)
- 'In-Format' screening of a novel bispecific antibody format reveals significant potency improvements relative to unformatted molecules (Q36175749) (← links)
- Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers. (Q47134203) (← links)
- Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries (Q49358130) (← links)
- Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies (Q60919458) (← links)
- A microfluidic competitive immuno-aggregation assay for high sensitivity cell secretome detection (Q89041922) (← links)
- Antigen recognition by single-domain antibodies: structural latitudes and constraints (Q89148188) (← links)